Premium
Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine‐resistant strains
Author(s) -
Hayashi Kazuhiko,
Katano Yoshiaki,
Ishigami Masatoshi,
Itoh Akihiro,
Hirooka Yoshiki,
Nakano Isao,
Yoshioka Kentaro,
Yano Motoyoshi,
Toyoda Hidenori,
Kumada Takashi,
Goto Hidemi
Publication year - 2010
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2009.06118.x
Subject(s) - lamivudine , medicine , virology , hepatitis b virus , hepatitis b , drug resistance , acute hepatitis b , hepatitis , virus , microbiology and biotechnology , biology , hbsag
Abstract Background and Aims: Acute hepatitis caused by lamivudine (LMV)‐resistant strains has not been reported, and the clinical impact of LMV‐resistant strains on acute hepatitis is not known. The aim of this study was to investigate the molecular and clinical characteristics of patients with acute hepatitis B caused by LMV‐resistant strains. Methods: Forty‐five patients with acute hepatitis B were studied. Hepatitis B virus (HBV) subgenotypes and LMV‐resistance mutations were determined by direct sequencing of the preS and polymerase regions, respectively. Results: HBV subgenotypes A2 ( n = 18), B1 ( n = 1), B2 ( n = 3), B3 ( n = 2), C1 ( n = 1), C2 ( n = 19) and C6 ( n = 1) were detected in patients with acute hepatitis. LMV‐resistance mutations were detected in two patients. LMV‐resistance mutations (L180M, M204I) were detected in a patient with subgenotype C2 who had acute self‐limited hepatitis. The other patient with LMV‐resistance mutations (L180M, M204V) was infected with subgenotype A2 and had severe hepatitis. Conclusion: LMV‐resistant strains are rare, but they are starting to be found in patients with acute hepatitis B. Surveillance for detecting drug‐resistant HBV strains would be important for clinical practice.